Knowing that the life sciences consulting market is growing is not particularly useful if you are trying to work out whether there is a role worth moving for in your specific area. What follows is a practice-by-practice view of where hiring is genuinely active in 2026 — grounded in what is actually happening in the market, not what the sector's growth statistics suggest should be happening.
Market Access and HEOR: consistently active, increasingly integrated
Market access and HEOR consulting is the largest practice area in the sector and it is still generating consistent senior hiring. The demand is real, but the shape of the roles being filled has changed. Firms are not looking for HEOR specialists and access strategists as two separate pools — they are looking for consultants who can hold both, or who are specialist enough in one that they can credibly lead engagements that span both workstreams with the right team around them.
The profiles in highest demand within this area are those with genuine depth in at least one major European market — NICE submissions in the UK, AMNOG in Germany, and HAS in France are the three most-cited areas of scarcity. Multi-market experience is a significant differentiator. Consultants who have worked across two or more of these frameworks are consistently seeing more interest and more competitive offers than those whose experience is single-market.
Geographically, London remains the primary UK hub for these roles. Across Europe, Zurich, Basel, and Amsterdam are generating consistent demand. In the US, the major east coast hubs — Boston, New York, and Philadelphia — dominate, though remote and hybrid models have meaningfully expanded the geographic scope of most searches.
Real-world evidence: fastest growth, thinnest talent pool
RWE consulting is generating the most active hiring growth in percentage terms. The gap between demand and supply is more acute here than in any other area of the sector. NICE's 2024 methods update formally incorporating RWE, and parallel EMA guidance reinforcing the same direction, has created a step-change in client demand that the talent market is struggling to meet.
The roles being created span from analyst and modelling specialist at the junior end through to practice leads and Directors at the senior end. At Director level, the firms growing fastest in this space are those that have accepted they cannot hire their way to capability — they have to grow it internally, which means the most active hiring at senior level tends to be for people who can lead and develop a team as much as they can personally deliver the technical work.
In RWE consulting, the shortage of senior talent is severe enough that firms are consistently hiring people at the edge of their stated criteria — prioritising depth in methodology or client leadership over the combination of both.
Launch strategy and New Product Planning: the momentum is real
The pipeline of late-stage pharmaceutical assets moving toward approval in oncology, cardiometabolic, and immunology is creating sustained demand for launch strategy and NPP consulting. GLP-1 launch strategy specifically — managing the commercial complexity of products with enormous market potential but fiercely competitive landscapes — is one of the highest-growth mandate types in specialist pharma boutiques right now.
For consultants in commercial strategy or NPP roles at Director or Principal level, the market in 2026 is unusually active. The scarcity is specific: firms need people who combine strategic credibility, therapeutic area depth, and the ability to manage complex multi-workstream engagements. That combination, at that level, is genuinely rare — which is why the same small group of people tends to be approached by multiple firms simultaneously when they become available.
Regulatory affairs consulting: steady demand, specialist profiles only
Regulatory consulting continues to generate consistent hiring, driven by the complexity of navigating simultaneous FDA, EMA, and MHRA submissions — and, increasingly, by the emerging PMDA and NMPA regulatory environments as firms support clients bringing products to Japan and China. The talent required is highly specialist: former agency personnel or industry regulatory leads with deep technical knowledge and the credibility to engage with health authorities directly on behalf of clients.
This is not a practice area where generalist consulting experience transfers easily. The firms hiring in regulatory consulting in 2026 are looking for people whose specific technical credentials are as important as their consulting capability.
The overall picture for senior candidates
Across all of these areas, the consistent signal is that specialism commands a premium in 2026 that it has not always commanded in the past. The market for experienced senior generalists — people who describe themselves as broad life sciences or commercial strategy consultants without a defined area of depth — is softer than it has been. The market for people with genuine, demonstrable expertise in a specific practice area and therapeutic context is as active as it has been for a decade.
If you are considering a move and want to understand where your profile sits in the current market, the most useful starting point is an honest assessment of what you are genuinely expert in — not what you have touched, but what you could lead a complex client engagement in without significant support from more senior colleagues.